Elza C. de Bruin - Concepedia

Author

Elza C. de Bruin

AstraZeneca (United Kingdom)

Also Known As

E.C. De Bruin, E.C. de Bruin, Elza C De Bruin, Elza C de Bruin, Elza C. de Bruin

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)The Christie NHS Foundation Trust Radboud University Nijmegen Leiden University Medical Center Vall d'Hebron Institute of Oncology

About

Elza C. de Bruin is an author at AstraZeneca (United Kingdom).

Elza C. de Bruin

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, New England Journal of Medicine	2023	600
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial Sarah Hrebien, Valentina Citi, Isaac García-Murillas, Annals of Oncology	2019	151
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial Sacha J. Howell, Angela Casbard, Margherita Carucci, The Lancet Oncology	2022	136
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong, Annals of Oncology	2019	83
Clinical impact of HLA class I expression in rectal cancer Frank M. Speetjens, Elza C. de Bruin, Hans Morreau, Cancer Immunology Immunotherapy	2007	53
Caspase-3 Activity Predicts Local Recurrence in Rectal Cancer Pieter de Heer, Elza C. de Bruin, Elma Meershoek‐Klein Kranenbarg, Clinical Cancer Research	2007	45
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts Albert Gris‐Oliver, Marta Palafox, Laia Monserrat, Clinical Cancer Research	2020	38
Cyclooxygenase 2 Expression in Rectal Cancer Is of Prognostic Significance in Patients Receiving Preoperative Radiotherapy Pieter de Heer, Marleen J.E.M. Gosens, Elza C. de Bruin, Clinical Cancer Research	2007	31

Page 1